About this trial
Chronic constipation is a common gastrointestinal disease with a global prevalence of about 15%, significantly affecting daily life and quality of life. Traditional treatments primarily rely on laxatives, which may lead to adverse effects with prolonged use, while surgical interventions have limited patient acceptance. Recent studies indicate that gut microbiota therapies-including probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT)-can effectively manage chronic constipation. This study aims to investigate the safety and efficacy of FMT combined with a prebiotic nutritional intervention (using a co-localization strategy) in the treatment of functional constipation. Additionally, the investigators will explore changes in fecal microbiota and metabolomic profiles following the treatment.
Eligibility criteria
Qualifiers
Age: 18 to 70.
Symptom requirements: The following at least 2 items should occur in ≥25% of bowel movements: a. Straining during defecation; b. Hard stool (Bristol Stool Classification score 1-2); c. Feeling of incomplete evacuation; d. Rectal obstruction sensation; e. Need for finger assistance during defecation; f. Spontaneous bowel movements <3 times per week.
It is rare to have loose stools without laxatives.
Exclusion of irritable bowel syndrome (IBS): IBS diagnosis criteria not meeting Rome IV.
Disqualifiers
Pregnancy or lactation.
Unable to take the intervention product or complete the examination as required.
Language expression disorder or mental illness.
Physical examination showed severe liver and kidney dysfunction.
Trial design
Treatments tested in this trial
- FMT